ProQR Therapeutics N.V. Ordinary Shares
PRQRProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic eye diseases and other rare genetic disorders. Founded in 2012 and based in the Netherlands, it specializes in designing therapies that target the root causes of these conditions, aiming to provide transformative treatments for patients with limited options.
Company News
ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomerâ„¢ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.
ProQR Therapeutics received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects for a Phase 1 study of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. The company will host a virtual investor event on November 3, 2025 to discuss the clinica...
ProQR Therapeutics reported its Q1 2025 financial results, highlighting progress in its Axiomer RNA editing pipeline, including the advancement of its lead program AX-0810 targeting NTCP for cholestatic diseases towards a CTA filing in Q2 2025. The company also strengthened its leadership team with new CFO and CMO appointments.
ProQR Therapeutics is advancing its Axiomer™ ADAR-mediated RNA editing pipeline, with plans to file a CTA for its lead program AX-0810 targeting NTCP for Cholestatic diseases in Q2 2025. The company expects up to four clinical data readouts in 2025 and 2026, and has a strong financial position with €149.4 million in cash and cash equivalents ...
ProQR Therapeutics, a company focused on RNA therapies, has appointed Dr. Peter Beal, a leading expert in ADAR and RNA biology, as its Chief ADAR Scientist. Dr. Beal will oversee the optimization and development of ProQR's Axiomer RNA editing platform.
